Candidates for intra-articular administration therapeutics and therapies of osteoarthritis

17Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

Abstract

Osteoarthritis (OA) of the knee is a disease that significantly decreases the quality of life due to joint deformation and pain caused by degeneration of articular cartilage. Since the degeneration of cartilage is irreversible, intervention from an early stage and control throughout life is important for OA treatment. For the treatment of early OA, the development of a disease-modifying osteoarthritis drug (DMOAD) for intra-articular (IA) injection, which is attracting attention as a point-of-care therapy, is desired. In recent years, the molecular mechanisms involved in OA progression have been clarified while new types of drug development methods based on gene sequences have been established. In addition to conventional chemical compounds and protein therapeutics, the development of DMOAD from the new modalities such as gene therapy and oligonucleotide therapeutics is accelerating. In this review, we have summarized the current status and challenges of DMOAD for IA injection, especially for protein therapeutics, gene therapy, and oligonucleotide therapeutics.

Cite

CITATION STYLE

APA

Toyoda, E., Maehara, M., Watanabe, M., & Sato, M. (2021, April 1). Candidates for intra-articular administration therapeutics and therapies of osteoarthritis. International Journal of Molecular Sciences. MDPI. https://doi.org/10.3390/ijms22073594

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free